Castle Biosciences
244 articles with Castle Biosciences
-
Study Shows Castle Biosciences’ Cutaneous Melanoma Gene Expression Profile Test Improves Identification Of High Risk Disease In Tumors Of Intermediate T2/T3 Thickness
6/2/2015
-
Castle Biosciences Expands Sales Force And Appoints Patrick Hall As Executive Director Of Medical Affairs, Promotes Robert W. Cook To Executive Director, R&D
5/28/2015
-
Castle Biosciences Hires Vice President Of Marketing
4/21/2015
-
Castle Biosciences Secures $6 Million Credit Facility From Silicon Valley Bank
4/14/2015
-
Study Shows Castle Biosciences’ Noninvasive Skin Melanoma Gene Test Improves Accuracy Of Sentinel Lymph Node Biopsy In Predicting Metastasis
3/5/2015
-
Castle Biosciences Announces New Director Appointment And CFO Hire
2/24/2015
-
Study Of Castle Biosciences’ Skin Melanoma Gene Test Published In Clinical Cancer Research
1/6/2015
-
Castle Biosciences’ Multi-Analyte Test Successfully Identifies Esophageal Cancer Patients Who Are Extremely Resistant To Standard Treatment Of Chemoradiation Therapy
10/23/2014
-
Castle Biosciences Snags $11.8 Million Financing
8/13/2014
-
Study Shows Castle Biosciences’ Gene Expression Profile Test Successfully Identified High Risk Disease In A Cohort Of 217 Melanoma Patients Who Underwent Sentinel Lymph Node Biopsy
6/2/2014
-
Castle Biosciences' Esophageal Cancer Test Accurately Predicts Pre-Surgical Treatment Response
6/2/2014
-
Castle Biosciences' Melanoma Gene Expression Profile Test To Be Subject Of Presentation At American Society of Clinical Oncology Annual Meeting
5/15/2014
-
Castle Biosciences' Esophageal Cancer Test Identifies Patients Who Are Resistant To Standard Pre-Surgical Chemoradiation Therapy
5/6/2014
-
Castle Biosciences' Mesothelioma Molecular Test Accurately Stratifies Survival Risk Under Surgical And Non-Surgical Treatment Plans
4/29/2014
-
Castle Biosciences Announces Data Demonstrating Ability To Identify Esophageal Cancer Patients Resistant To Standard Pre-Surgical Treatment Of Chemotherapy And Radiation
1/16/2014
-
Castle Biosciences Launches Tissue Repository for Eye Cancer Patients
9/30/2013
-
Castle Biosciences Genetic Test Highly Accurate in Differentiating Thymomas From Thymic Carcinoma Tumors
9/25/2013
-
Castle Biosciences Release: Gene Test Identifies Non-Metastatic Melanoma Patients at High Risk of Recurrence
8/5/2013
-
Castle Biosciences Release: New Website Dedicated to Patients With Thymic Cancer
7/30/2013
-
Castle Biosciences Release: Gene Test Highly Accurate in Predicting Metastasis in Patients With Thymoma
7/25/2013